(A) Agilent Technologies - Ratings and Ratios
Chromatography, Spectrometry, Genomics, Diagnostics, Laboratory Supplies
A EPS (Earnings per Share)
A Revenue
Description: A Agilent Technologies
Agilent Technologies Inc (NYSE:A) is a leading provider of application-focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, operating through three main segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.
The companys diverse product portfolio includes liquid chromatography and mass spectrometry systems, gas chromatography systems, spectroscopy instruments, laboratory software, and automation systems, catering to various industries such as pharmaceuticals, biotechnology, and environmental monitoring.
From a financial perspective, Agilent Technologies has demonstrated a strong track record of revenue growth and profitability, driven by its innovative products and strategic acquisitions. Key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating margin are crucial in evaluating the companys financial health. For instance, a high gross margin indicates the companys ability to maintain pricing power and control costs.
Additionally, Agilents return on equity (RoE) of 19.46% suggests that the company is generating strong returns for its shareholders. The price-to-earnings (P/E) ratio of 30.58 and forward P/E of 19.61 indicate that the stock may be slightly overvalued, but expectations of future growth are high. Other important metrics to consider include the companys dividend yield, debt-to-equity ratio, and research and development (R&D) expenses as a percentage of revenue.
To further evaluate Agilents stock performance, it is essential to analyze its technical indicators, such as relative strength index (RSI), Bollinger Bands, and moving averages. A comprehensive analysis of these indicators can provide insights into the stocks trend, momentum, and potential trading opportunities.
A Stock Overview
| Market Cap in USD | 35,696m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1999-11-18 |
A Stock Ratings
| Growth Rating | -26.2% |
| Fundamental | 62.8% |
| Dividend Rating | 53.2% |
| Return 12m vs S&P 500 | -23.5% |
| Analyst Rating | 4.0 of 5 |
A Dividends
| Dividend Yield 12m | 0.79% |
| Yield on Cost 5y | 1.02% |
| Annual Growth 5y | 12.10% |
| Payout Consistency | 67.2% |
| Payout Ratio | 18.0% |
A Growth Ratios
| Growth Correlation 3m | 40.8% |
| Growth Correlation 12m | -69.3% |
| Growth Correlation 5y | -2% |
| CAGR 5y | -1.04% |
| CAGR/Max DD 3y | -0.03 |
| CAGR/Mean DD 3y | -0.07 |
| Sharpe Ratio 12m | -0.86 |
| Alpha | -26.38 |
| Beta | 0.711 |
| Volatility | 28.65% |
| Current Volume | 959.6k |
| Average Volume 20d | 1482.5k |
| Stop Loss | 119.5 (-3%) |
| Signal | 0.75 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (1.22b TTM) > 0 and > 6% of Revenue (6% = 407.3m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -1.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 34.78% (prev 28.74%; Δ 6.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.50b > Net Income 1.22b (YES >=105%, WARN >=100%) |
| Net Debt (1.87b) to EBITDA (1.47b) ratio: 1.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (285.0m) change vs 12m ago -2.06% (target <= -2.0% for YES) |
| Gross Margin 52.96% (prev 54.39%; Δ -1.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 58.46% (prev 59.09%; Δ -0.62pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.96 (EBITDA TTM 1.47b / Interest Expense TTM 117.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.52
| (A) 0.19 = (Total Current Assets 4.25b - Total Current Liabilities 1.89b) / Total Assets 12.23b |
| (B) 0.09 = Retained Earnings (Balance) 1.10b / Total Assets 12.23b |
| (C) 0.12 = EBIT TTM 1.40b / Avg Total Assets 11.61b |
| (D) 0.14 = Book Value of Equity 822.0m / Total Liabilities 5.86b |
| Total Rating: 2.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.82
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 3.67% = 1.84 |
| 3. FCF Margin 20.65% = 5.16 |
| 4. Debt/Equity 0.63 = 2.31 |
| 5. Debt/Ebitda 2.74 = -1.37 |
| 6. ROIC - WACC 4.74% = 5.92 |
| 7. RoE 19.97% = 1.66 |
| 8. Rev. Trend -42.00% = -2.10 |
| 9. Rev. CAGR -2.23% = -0.37 |
| 10. EPS Trend -29.51% = -0.74 |
| 11. EPS CAGR -3.94% = -0.49 |
What is the price of A shares?
Over the past week, the price has changed by -4.28%, over one month by +5.05%, over three months by +3.86% and over the past year by -8.95%.
Is Agilent Technologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of A is around 110.80 USD . This means that A is currently overvalued and has a potential downside of -10.09%.
Is A a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the A price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 138.2 | 12.1% |
| Analysts Target Price | 138.2 | 12.1% |
| ValueRay Target Price | 122.8 | -0.4% |
Last update: 2025-09-02 02:46
A Fundamental Data Overview
CCE Cash And Equivalents = 1.53b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 29.2914
P/E Forward = 20.79
P/S = 5.2586
P/B = 5.6037
P/EG = 1.9595
Beta = 1.219
Revenue TTM = 6.79b USD
EBIT TTM = 1.40b USD
EBITDA TTM = 1.47b USD
Long Term Debt = 3.96b USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 59.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (Calculated: Short Term 59.0m + Long Term 3.96b)
Net Debt = 1.87b USD (from netDebt column, last quarter)
Enterprise Value = 38.18b USD (35.70b + Debt 4.02b - CCE 1.53b)
Interest Coverage Ratio = 11.96 (Ebit TTM 1.40b / Interest Expense TTM 117.0m)
FCF Yield = 3.67% (FCF TTM 1.40b / Enterprise Value 38.18b)
FCF Margin = 20.65% (FCF TTM 1.40b / Revenue TTM 6.79b)
Net Margin = 17.97% (Net Income TTM 1.22b / Revenue TTM 6.79b)
Gross Margin = 52.96% ((Revenue TTM 6.79b - Cost of Revenue TTM 3.19b) / Revenue TTM)
Tobins Q-Ratio = 46.45 (Enterprise Value 38.18b / Book Value Of Equity 822.0m)
Interest Expense / Debt = 0.70% (Interest Expense 28.0m / Debt 4.02b)
Taxrate = 15.25% (232.0m / 1.52b)
NOPAT = 1.19b (EBIT 1.40b * (1 - 15.25%))
Current Ratio = 2.25 (Total Current Assets 4.25b / Total Current Liabilities 1.89b)
Debt / Equity = 0.63 (Debt 4.02b / last Quarter total Stockholder Equity 6.37b)
Debt / EBITDA = 2.74 (Net Debt 1.87b / EBITDA 1.47b)
Debt / FCF = 2.87 (Debt 4.02b / FCF TTM 1.40b)
Total Stockholder Equity = 6.11b (last 4 quarters mean)
RoA = 9.98% (Net Income 1.22b, Total Assets 12.23b )
RoE = 19.97% (Net Income TTM 1.22b / Total Stockholder Equity 6.11b)
RoCE = 13.89% (Ebit 1.40b / (Equity 6.11b + L.T.Debt 3.96b))
RoIC = 12.56% (NOPAT 1.19b / Invested Capital 9.44b)
WACC = 7.82% (E(35.70b)/V(39.72b) * Re(8.64%)) + (D(4.02b)/V(39.72b) * Rd(0.70%) * (1-Tc(0.15)))
Shares Correlation 3-Years: -91.50 | Cagr: -0.40%
Discount Rate = 8.64% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.14% ; FCFE base≈1.41b ; Y1≈1.41b ; Y5≈1.49b
Fair Price DCF = 83.25 (DCF Value 23.65b / Shares Outstanding 284.1m; 5y FCF grow -0.63% → 3.0% )
Revenue Correlation: -42.00 | Revenue CAGR: -2.23%
Rev Growth-of-Growth: 10.77
EPS Correlation: -29.51 | EPS CAGR: -3.94%
EPS Growth-of-Growth: 9.24
Additional Sources for A Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle